8 completed, 5 unknown, 4 recruiting, 1 available. 7 Phase 2, 4 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 4 | Completed 3, Recruiting 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Pulmonary Alveolar Proteinosis: new trials by email Literature Review of Pulmonary Alveolar Proteinosis trials Research Report on Pulmonary Alveolar Proteinosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Molgramostim - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Recruiting | Savara Inc. | 5 | 2025-10-22 | 2026-02-19 |
| Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis GM-CSF (granulocyte-macrophage colony-stimulating factor) - Pulmonary Alveolar Proteinosis | Phase 2 | Not yet recruiting | Jiuwu Bai | 10 | 2025-07-01 | 2025-05-25 |
| Safety and Efficacy of PMT Therapy of hPAP Gene-Corrected Macrophages administered by bronchoscopic instillation - Hereditary Pulmonary Alveolar Proteinosis | Phase 1 / Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 3 | 2023-06-26 | 2025-12-19 |
| Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis adenosine deaminase test - Pulmonary Alveolar Proteinosis | Unknown | TRPHARM | 15 | 2021-08-16 | 2022-03-29 | |
| Macrophages, GM-CSF and MARS Proteinosis Blood collection, Bronchoalveolar lavage fluid collection - Pulmonary Alveolar Proteinosis (PAP), MARS | Completed | Assistance Publique - Hôpitaux de Paris | 20 | 2021-06-07 | 2026-04-03 | |
| The Study of Mesenchymal Stem Cells Treat Autoimmune Pulmonary Alveolar Proteinosis in Vitro Pulmonary Alveolar Proteinosis(PAP) | Unknown | Guangzhou Institute of Respiratory Disease | 26 | 2021-03-01 | 2023-03-21 | |
| Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution - Pulmonary Alveolar Proteinosis, COPD | Early Phase 1 | Unknown | Black Tie Medical, Inc. | 10 | 2020-03-25 | 2023-02-22 |
| Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis Assesssing the severity of pulmonary alveolar proteinosis - Pulmonary Alveolar Proteinosis | Completed | Shanghai Pulmonary Hospital, Shanghai, China | 231 | 2020-01-01 | 2022-03-09 | |
| Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. Methionine, Vitamin B12, B9, B6, C supplementation, Methionine/homocysteine Dosage - Pulmonary Alveolar Proteinosis, Mutation Ala393Thr of the MARS Gene | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 3 | 2019-09-16 | 2025-11-20 |
| Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis GM-CSF - Pulmonary Alveolar Proteinosis, Treatment | Phase 2 | Unknown | Dai Huaping | 60 | 2016-08-01 | 2017-10-20 |
| Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Molgramostim, Placebo - Pulmonary Alveolar Proteinosis, Bronchiectasis | Phase 1 | Completed | Savara Inc. | 42 | 2015-05-01 | 2017-02-23 |
| A National Registry For Pulmonary Alveolar Proteinosis Pulmonary Alveolar Proteinosis | Recruiting | Children's Hospital Medical Center, Cincinnati | 500 | 2015-04-01 | 2026-03-17 | |
| Rituximab for Anti-cytokine Autoantibody-Associated Diseases Rituximab - Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 7 | 2014-04-29 | 2026-10-16 |
| European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis | Recruiting | Matthias Griese | 1000 | 2013-12-01 | 2022-09-21 | |
| Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT Pulmonary Alveolar Proteinosis | Completed | Children's Hospital Medical Center, Cincinnati | 9 | 2013-12-01 | 2018-11-01 | |
| Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. rhGM-CSF, Whole Lung Lavage(WLL) - Pulmonary Alveolar Proteinosis | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 40 | 2012-01-01 | 2013-11-18 |
| Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial Retrospective Chart Review - Pulmonary Alveolar Proteinosis | Completed | Children's Hospital Medical Center, Cincinnati | 73 | 2007-07-01 | 2017-01-02 | |
| Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis rituximab - Pulmonary Alveolar Proteinosis, Primary Disease | Phase 2 | Completed | East Carolina University | 10 | 2007-01-01 | 2023-09-28 |
| GM-CSF in Patients With Pulmonary Alveolar Proteinosis GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) - Pulmonary Alveolar Proteinosis | Phase 2 | Terminated | The Cleveland Clinic | 48 | 2001-09-01 | 2015-03-25 |
| Molgramostim Nebulizer Solution Expanded Access Program Protocol Molgramostim nebulizer solution - Autoimmune Pulmonary Alveolar Proteinosis | Available | Savara Inc. | 2026-10-13 |
Lung Diseases, Interstitial (2) · Pulmonary Alveolar Proteinosis, Acquired (2) · Bronchiectasis (1) · Candidiasis, Chronic Mucocutaneous (1) · Coronavirus Infections (1) · Cystic Fibrosis (1) · Idiopathic Pulmonary Fibrosis (1) · Pneumonia, Viral (1) · Pulmonary Disease, Chronic Obstructive (1) · Pulmonary Eosinophilia (1) · Pulmonary Fibrosis (1) · Respiratory Distress Syndrome (1) · Respiratory Distress Syndrome, Newborn (1)
Lung Diseases (20) · Respiratory Tract Diseases (20) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Chronic Disease (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Disease Attributes (2) · Infant, Newborn, Diseases (2) · Infections (2) · Respiration Disorders (2) · Bacterial Infections and Mycoses (1) · Bronchial Diseases (1) · Candidiasis (1) · Coronaviridae Infections (1) · Dermatomycoses (1)
Colony-Stimulating Factors (4) · Granulocyte-Macrophage Colony-Stimulating Factor (4) · regramostim (4) · Rituximab (2) · molgramostim (2) · Blood Specimen Collection (1) · Methionine (1) · Vitamin B 12 (1) · sargramostim (1)
Children's Hospital Medical Center, Cincinnati (4) · Savara Inc. (3) · Assistance Publique - Hôpitaux de Paris (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Black Tie Medical, Inc. (1) · Dai Huaping (1) · East Carolina University (1) · Guangzhou Institute of Respiratory Disease (1) · Jiuwu Bai (1) · Matthias Griese (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · TRPHARM (1) · The Cleveland Clinic (1)
United States (9) · China (4) · Germany (3) · France (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Italy (1) · Japan (1)
Bruce C Trapnell, MD (1) · Bruce Trapnell (1) · Christa S Zerbe, M.D. (1) · Christopher Towe, MD (1) · Huiping Li, Dr (1) · Jason Woods, MD (1) · Johnston Steward, MD (1) · Mani S Kavuru, MD (1) · Matthias Griese, MD, (1) · Matthias Griese, Prof. (1) · Robert W Alexander, MD (1) · Xinlun Tian, Dr (1) · Yonglong Xiao, Dr (1)
PMID 21478218, PMID 31898493, PMID 34503986, PMID 36824611, PMID 40973220, PMID 42341791
2018 (1), R33HL156888 (1), U54HL127672 (1)